SuicideNCT05671133
Effectiveness and Implementation of a Clinician Decision Support System to Prevent Suicidal Behaviors
A study testing Clinician Decision Support Tool in people with Suicide and Suicide, Attempted, run by Massachusetts General Hospital at 1 site in United States.
Trial summary
The primary aim of this project are to evaluate a comprehensive, practice-ready, and deployment-focused strategy for improving the prediction and prevention of suicide attempts among a sample of 4,000 patients presenting to an ED with a psychiatric concern. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Suicide, Suicide, Attempted
- What is being tested?
- Clinician Decision Support Tool
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4,000 participants
- Where
- 1 siteUnited States
- Study dates
- 25 Feb 2025to 28 Sep 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adult status (≥18 years-old);
- Willing to provide an email address;
- Presentation at the APS
Who cannot join
- Inability to understand the study procedures and provide informed consent such as those with gross cognitive impairment (including florid psychosis), intellectual disability, dementia, acute intoxication, or the presence of extremely agitated or violent behavior
- Decisions about inclusion/exclusion criteria will be made by the emergency department providers on duty at the time. These broad inclusion criteria maximize the clinical applicability of obtained results while the exclusion criteria ensure the ethical principle of respect for persons.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Amy Ahn, PhD contact
United States1 site, 1 recruiting
- Recruiting
Massachusetts General Hospital
Boston, Massachusetts, 02114
Matthew Nock, 6174964484, nock@wjh.harvard.edu
About this study
The primary aim of this project are to evaluate a comprehensive, practice-ready, and deployment-focused strategy for improving the prediction and prevention of suicide attempts among a sample of 4,000 patients presenting to an ED with a psychiatric concern. The first aim is to evaluate the effects of providing information about risk of patient suicidal behavior to ED clinicians. The investigators hypothesize that patients randomly assigned to have their clinician receive their risk score will have a lower rate of suicide attempts during 6-month follow-up and that this effect will be mediated by changes in clinician decision-making.
Read the detailed description
This study is designed to test the effects of providing emergency department (ED) clinicians with enhanced information about their patients' risk of a suicide attempt in the 6-months after leaving the ED. The study will be conducted in five EDs. The primary study will be conducted in four EDs within Mass General Brigham (MGB): Massachusetts General Hospital (MGH), MGB-Salem, Brigham and Women's Hospital (BWH), and Brigham and Women's Faulkner Hospital (BWFH). The investigators propose to enroll 4,000 participants over the study period and to provide the treating clinician with a risk score for a randomly selected half of those 4,000 participants. The primary outcome will be rate of suicide attempts over the next 6-months. It is anticipated that provision of this risk score will change clinician decision-making, leading clinicians to be more likely to hospitalize high-risk patients and less likely to hospitalize low-risk patients. A smaller (N=250) pilot implementation study has been added in a new non-MGB ED at Cambridge Health Alliance (CHA).
The primary study will enroll 4,000 patients presenting to the ED at MGH MGB-Salem, BWH, and BWFH. Study inclusion criteria include presentation to the ED, adult status (≥18 years-old), and ability to provide an email address.
Exclusion criteria include the presence of any factor that impairs an individual's ability to comprehend and effectively participate in the study, including an inability to speak or write English fluently, the presence of gross cognitive impairment due to florid psychosis, intellectual disability, dementia, acute intoxication, or the presence of extremely agitated or violent behavior. These broad inclusion criteria maximize the clinical applicability of results while the exclusion criteria ensure the ethical principle of respect for persons.
According to prior studies in the MGB system, investigators anticipate the MGB sample will be about 73% White/European American, 9% African-American, 4% Asian American, and the remainder of other or mixed ethnicity. The implementation study will enroll 250 patients presenting to the ED at CHA and will have the same inclusion/exclusion criteria as the primary study. Based on recent numbers reported in the CHA 2021 Annual Report, it is anticipated that the CHA sample will be about 37% White/European American, 16% African- American, 9% Asian American, and the remainder of other or mixed ethnicity.
Study Research Assistants (RAs) will use well-established protocols of reviewing patients presenting to the ED, where investigators have been conducting IRB approved research on the prediction of suicidal behavior for >15 years. RAs will first consult potentially eligible patients' assigned clinician to obtain their permission to approach the patient to briefly describe the study and ask if they are interested in learning more about it. Only those patients determined to meet the inclusion/exclusion criteria will be approached. To further ensure communication between the research and clinical team, investigators will give a presentation about the study to the ED clinical teams before starting recruitment and at regular intervals throughout the award period. RAs will obtain written informed consent from participants (using REDCap, described below) while in the ED, and administer a baseline self-report assessment battery (on an iPad). Contact information (including the full name, phone number, and if available, email address for both the participant and a collateral contact for emergency situations) will be collected via secure REDCap data collection surveys at baseline, and with participants' permission, select health data (e.g., readmission for a suicide attempt over the next 6 months) will be extracted from the EHR (and stored in a de-identified database). Participants will receive an email-based survey to assess the receipt of treatment and the presence of a suicide attempt at 1-month and 6-months after their ED visit. Participants will receive financial incentives for each survey completed.
In the primary study, after completing a brief baseline assessment, participants will be randomly assigned (1:1) to have their clinician receive a predicted probability that this patient will make a suicide attempt after leaving the ED. There is no intervention with the patient themselves. Investigators hypothesize that clinicians receiving this evidence-based prediction score will be more likely to hospitalize high-risk patients and less likely to hospitalize low-risk patients and that this will lead to a decrease in the rate of suicide attempts in the experimental condition relative to the control condition. The primary endpoint in this study is suicide attempt during the six months post-randomization. Suicide attempts will be measured using two methods: (a) self-report surveys and (b) documentation in the EHR during the follow-up period. Self-report questions about suicide attempts will be those from the Self-Injurious Thoughts and Behaviors Interview (SITBI), a widely used measure of suicidal thoughts and behaviors with strong reliability and validity and one of the measures recommended in the PhenX toolkit. Investigators also will examine all new medical records during the 6-months following each participant's index ED visit to determine if the participant revisited the hospital due to suicide ideation or suicide attempt during the follow-up period. This approach has been used in prior studies to measure such outcomes. In prior work in the APS we have found high agreement between self-reports on the SITBI and the documentation of suicide attempts in electronic medical records (K=.84). Secondary endpoints are suicide attempt within 1-month post-randomization. Additional exploratory hypotheses are: (1) among patients estimated by the model to be high-risk, clinicians of patients in the experimental condition will be more likely to recommend hospitalization than clinicians of patients in the control condition; (2) among patients estimated to be at intermediate risk, clinicians of patients in the experimental condition are (a) less likely to recommend hospitalization and (b) more likely to recommend partial hospitalization compared to clinicians of patients in the control condition, and (3) among patients estimated to be at low risk, clinicians of patients in the experimental condition are more likely to discharge to home than clinicians of patients in the control condition. Investigators will additionally investigate the mediating role of clinician choice on the association between the intervention and patient outcomes using mediation analysis.
- Conditions
- Suicide, Suicide, Attempted
- Being tested
- Clinician Decision Support Tool
- Medical subject headings
- Suicide, Suicide, Attempted
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clinician Decision Support ToolDiagnostic test
Clinician Decision Support Tool that provides information about patient's statistical probability of suicide attempt in next 1 month
| Study group | Role | What they receive |
|---|---|---|
| Experimental | Experimental | Investigators will use previously developed EHR-derived machine- learning-based model to generate predicted probability risk scores of 1-month suicide attempt for each patient. The EHR-derived risk score will be combined with the patient self-report data (initially from the 20-question screener) to generate composite predicted risk scores (based on the most updated ML model developed by investigators via the ensemble ML Super Learner [SL] method) for the patient within minutes of the patient completing the self-report survey. Risk scores will be provided to the clinician while the patient is in the ED. This feedback includes information about the patient's relative risk compared to other psychiatric patients seen in the ED and the risk factors contributing to this level of risk. Receives: Diagnostic Test: Clinician Decision Support Tool |
| Control | No intervention | Patient's clinician is not given Clinician Decision Support Tool (care as usual) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Suicide attempt
The primary endpoint is the occurrence (0,1) of a suicide attempt during the 6 months following randomization. The outcome will be measured as a single binary variable, indicating whether a participant experienced at least one suicide attempt during the follow-up period. This outcome will be ascertained using participant self-report and EHR documentation. Self-reported suicide attempts will be assessed using questions from the Self-Injurious Thoughts and Behaviors Interview (SITBI), a widely used measure of suicidal thoughts and behaviors with strong reliability and validity and one of the measures recommended in the PhenX Toolkit. EHR review will further identify documented suicide attempts during follow-up. Information from both sources will be used to determine a single outcome value for each participant. The singular outcome measure is the occurrence of at least one suicide attempt during follow-up (Yes/No; 0,1) as identified by either source (self-report or EHR).
Measured: 6-months
Secondary outcomes (1)
Suicide attempt
Secondary endpoints are suicide attempt (using the same assessment methods as the primary endpoint) within 1-month post-randomization and will also be assessed using two sample tests of proportions.
Measured: 1-month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jan 2023
- Study start25 Feb 2025
- Primary completion31 May 2028 (estimated)
- Study completion28 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SuicideStudies of the same condition, open and under way.
- More trials run by Massachusetts General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 4,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Massachusetts General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Matthew K. Nock, PhD, Massachusetts General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05671133
- Sponsor's protocol ID
- 2022P002689
- Status last verified
- Jun 2026
- First submitted
- 16 Dec 2022
- Last updated
- 22 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Yes: All data will be shared via the National Institute of Mental Health National Data Archive
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness and Implementation of a Clinician Decision Support System to Prevent Suicidal Behaviors
- ClinicalTrials.gov ID
- NCT05671133
- Acronym / sponsor ID
- 2022P002689
- Conditions
- Suicide, Suicide, Attempted
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 4,000 participants (estimated)
- Lead sponsor
- Massachusetts General HospitalUniversity, hospital or other
- Study start
- 25 Feb 2025 (actual)
- Primary completion
- 31 May 2028 (estimated)
- Study completion
- 28 Sep 2028 (estimated)
- First posted
- 4 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary aim of this project are to evaluate a comprehensive, practice-ready, and deployment-focused strategy for improving the prediction and prevention of suicide attempts among a sample of 4,000 patients presenting to an ED with a psychiatric concern. The first aim is to evaluate the effects of providing information about risk of patient suicidal behavior to ED clinicians. The investigators hypothesize that patients randomly assigned to have their clinician receive their risk score will have a lower rate of suicide attempts during 6-month follow-up and that this effect will be mediated by changes in clinician decision-making.
Detailed description
This study is designed to test the effects of providing emergency department (ED) clinicians with enhanced information about their patients' risk of a suicide attempt in the 6-months after leaving the ED. The study will be conducted in five EDs. The primary study will be conducted in four EDs within Mass General Brigham (MGB): Massachusetts General Hospital (MGH), MGB-Salem, Brigham and Women's Hospital (BWH), and Brigham and Women's Faulkner Hospital (BWFH). The investigators propose to enroll 4,000 participants over the study period and to provide the treating clinician with a risk score for a randomly selected half of those 4,000 participants. The primary outcome will be rate of suicide attempts over the next 6-months. It is anticipated that provision of this risk score will change clinician decision-making, leading clinicians to be more likely to hospitalize high-risk patients and less likely to hospitalize low-risk patients. A smaller (N=250) pilot implementation study has been added in a new non-MGB ED at Cambridge Health Alliance (CHA).
The primary study will enroll 4,000 patients presenting to the ED at MGH MGB-Salem, BWH, and BWFH. Study inclusion criteria include presentation to the ED, adult status (≥18 years-old), and ability to provide an email address.
Exclusion criteria include the presence of any factor that impairs an individual's ability to comprehend and effectively participate in the study, including an inability to speak or write English fluently, the presence of gross cognitive impairment due to florid psychosis, intellectual disability, dementia, acute intoxication, or the presence of extremely agitated or violent behavior. These broad inclusion criteria maximize the clinical applicability of results while the exclusion criteria ensure the ethical principle of respect for persons.
According to prior studies in the MGB system, investigators anticipate the MGB sample will be about 73% White/European American, 9% African-American, 4% Asian American, and the remainder of other or mixed ethnicity. The implementation study will enroll 250 patients presenting to the ED at CHA and will have the same inclusion/exclusion criteria as the primary study. Based on recent numbers reported in the CHA 2021 Annual Report, it is anticipated that the CHA sample will be about 37% White/European American, 16% African- American, 9% Asian American, and the remainder of other or mixed ethnicity.
Study Research Assistants (RAs) will use well-established protocols of reviewing patients presenting to the ED, where investigators have been conducting IRB approved research on the prediction of suicidal behavior for >15 years. RAs will first consult potentially eligible patients' assigned clinician to obtain their permission to approach the patient to briefly describe the study and ask if they are interested in learning more about it. Only those patients determined to meet the inclusion/exclusion criteria will be approached. To further ensure communication between the research and clinical team, investigators will give a presentation about the study to the ED clinical teams before starting recruitment and at regular intervals throughout the award period. RAs will obtain written informed consent from participants (using REDCap, described below) while in the ED, and administer a baseline self-report assessment battery (on an iPad). Contact information (including the full name, phone number, and if available, email address for both the participant and a collateral contact for emergency situations) will be collected via secure REDCap data collection surveys at baseline, and with participants' permission, select health data (e.g., readmission for a suicide attempt over the next 6 months) will be extracted from the EHR (and stored in a de-identified database). Participants will receive an email-based survey to assess the receipt of treatment and the presence of a suicide attempt at 1-month and 6-months after their ED visit. Participants will receive financial incentives for each survey completed.
In the primary study, after completing a brief baseline assessment, participants will be randomly assigned (1:1) to have their clinician receive a predicted probability that this patient will make a suicide attempt after leaving the ED. There is no intervention with the patient themselves. Investigators hypothesize that clinicians receiving this evidence-based prediction score will be more likely to hospitalize high-risk patients and less likely to hospitalize low-risk patients and that this will lead to a decrease in the rate of suicide attempts in the experimental condition relative to the control condition. The primary endpoint in this study is suicide attempt during the six months post-randomization. Suicide attempts will be measured using two methods: (a) self-report surveys and (b) documentation in the EHR during the follow-up period. Self-report questions about suicide attempts will be those from the Self-Injurious Thoughts and Behaviors Interview (SITBI), a widely used measure of suicidal thoughts and behaviors with strong reliability and validity and one of the measures recommended in the PhenX toolkit. Investigators also will examine all new medical records during the 6-months following each participant's index ED visit to determine if the participant revisited the hospital due to suicide ideation or suicide attempt during the follow-up period. This approach has been used in prior studies to measure such outcomes. In prior work in the APS we have found high agreement between self-reports on the SITBI and the documentation of suicide attempts in electronic medical records (K=.84). Secondary endpoints are suicide attempt within 1-month post-randomization. Additional exploratory hypotheses are: (1) among patients estimated by the model to be high-risk, clinicians of patients in the experimental condition will be more likely to recommend hospitalization than clinicians of patients in the control condition; (2) among patients estimated to be at intermediate risk, clinicians of patients in the experimental condition are (a) less likely to recommend hospitalization and (b) more likely to recommend partial hospitalization compared to clinicians of patients in the control condition, and (3) among patients estimated to be at low risk, clinicians of patients in the experimental condition are more likely to discharge to home than clinicians of patients in the control condition. Investigators will additionally investigate the mediating role of clinician choice on the association between the intervention and patient outcomes using mediation analysis.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental | Experimental | Diagnostic Test: Clinician Decision Support ToolInvestigators will use previously developed EHR-derived machine- learning-based model to generate predicted probability risk scores of 1-month suicide attempt for each patient. The EHR-derived risk score will be combined with the patient self-report data (initially from the 20-question screener) to generate composite predicted risk scores (based on the most updated ML model developed by investigators via the ensemble ML Super Learner [SL] method) for the patient within minutes of the patient completing the self-report survey. Risk scores will be provided to the clinician while the patient is in the ED. This feedback includes information about the patient's relative risk compared to other psychiatric patients seen in the ED and the risk factors contributing to this level of risk. |
| Control | No intervention | –Patient's clinician is not given Clinician Decision Support Tool (care as usual) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adult status (≥18 years-old);
- Willing to provide an email address;
- Presentation at the APS
Key exclusion criteria (2 listed)
- Inability to understand the study procedures and provide informed consent such as those with gross cognitive impairment (including florid psychosis), intellectual disability, dementia, acute intoxication, or the presence of extremely agitated or violent behavior
- Decisions about inclusion/exclusion criteria will be made by the emergency department providers on duty at the time. These broad inclusion criteria maximize the clinical applicability of obtained results while the exclusion criteria ensure the ethical principle of respect for persons.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clinician Decision Support ToolClinician Decision Support Tool that provides information about patient's statistical probability of suicide attempt in next 1 month | Diagnostic test | Experimental |
Primary outcome
Suicide attempt
Time frame: 6-months
The primary endpoint is the occurrence (0,1) of a suicide attempt during the 6 months following randomization. The outcome will be measured as a single binary variable, indicating whether a participant experienced at least one suicide attempt during the follow-up period. This outcome will be ascertained using participant self-report and EHR documentation. Self-reported suicide attempts will be assessed using questions from the Self-Injurious Thoughts and Behaviors Interview (SITBI), a widely used measure of suicidal thoughts and behaviors with strong reliability and validity and one of the measures recommended in the PhenX Toolkit. EHR review will further identify documented suicide attempts during follow-up. Information from both sources will be used to determine a single outcome value for each participant. The singular outcome measure is the occurrence of at least one suicide attempt during follow-up (Yes/No; 0,1) as identified by either source (self-report or EHR).
1 secondary outcome
Suicide attempt
Time frame: 1-month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2026.
- Individual participant dataSharing planned: Yes. All data will be shared via the National Institute of Mental Health National Data Archive
Related trials for Suicide
Active, not recruitingObservational study
The Developmental Origins of Suicide Mortality
Suicide Mortality
Recruiting
Preventing Suicidal Behavior With Diverse High-Risk Youth in Acute Care Settings
Suicide, Attempted, Suicide Ideation
Not yet recruiting
Deaf CBT-TS to Reduce Suicide Risk
Depression - Major Depressive Disorder, Anxiety
Not yet recruiting
A Pre-post Study of a Lethal Means Safety Planning Intervention for Youth at Elevated Suicide Risk in the Emergency Department.
Suicidal Ideas, Suicidal Ideation
Active, not recruiting
Parent Intervention for Psychiatrically-Hospitalized Youth
Adolescent - Emotional Problem, Suicide and Self-harm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Amy Ahn, PhD contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Clinician Decision Support Tool in people with Suicide and Suicide, Attempted, run by Massachusetts General Hospital at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Matthew Nock, PhD (617-496-4484, nock@wjh.harvard.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Suicide attempt (time frame: 6-months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2026.